We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cisbio Bioassays Establishes Sales Operations in Asia

By LabMedica International staff writers
Posted on 30 Nov 2009
Print article
Cisbio Bioassays (Bagnols-sur-Cèze, France), a member of the IBA group (Louvain-la-Neuve, Belgium), has established sales operations in China and South Korea, expanding its presence in Asia. The company is a developer of homogeneous time-resolved fluorescence (HTRF) technology and services for assay development and drug screening. HTRF is a highly sensitive, robust technology for the detection of molecular interactions.

Sales of Cisbio Bioassays' HTRF-based tools, which include IP-One, cAMP, and Cellul'erk assays, and the Tag-lite cell surface receptor platform, will be handled in China by IBA China, IBA group's Beijing- based subsidiary. Sales in South Korea will be handled by JCBio Co., Ltd., a Seoul-based distributor specialized in products used by pharmaceutical and biotechnology laboratories. The local sales teams will enable the company to offer its G-protein coupled receptors (GPCR) and kinase technology platforms, biomarker assays, and related services to customers in pharmaceutical and biotechnology markets.

In addition to its HTRF- based tools, the company offers a range of services, including custom labeling of specific assay components, custom assay design and development, and HTRF technology training. The company is a global developer of products and technologies used for in vitro diagnostics (IVD) and assay development for drug screening procedures. In addition, Cisbio Bioassays produces a selection of biologic reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Cisbio Bioassays won the Frost & Sullivan (Palo Alto, CA, USA) 2009 North American Technological Innovation of the Year Award.

IBA is primarily active in the medical industry. It develops and markets equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus gained to provide electron accelerators for industrial sterilization and ionization.

Related Links:
Cisbio Bioassays
IBA group
IBA China
JCBio

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Automated Blood Typing System
IH-500 NEXT
New
PSA Test
Human Semen Rapid Test
New
Liquid Based Cytology Production Machine
LBP-4032

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.